SCHEMBL2218499

SCHEMBL2218499

O=c1cc(-c2ccc(O)c(O)c2)oc2cc(O)c(O)cc12

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLH Q9Y253 5/20 0.75
ALOX5 P09917 4/20 0.75
TNKS O95271 3/20 0.75
PARP1 P09874 3/20 0.75
TNKS2 Q9H2K2 3/20 0.75
KDM4E B2RXH2 6/20 0.72
MAPT P10636 6/20 0.72
ALOX15 P16050 5/20 0.72
HSD17B10 Q99714 5/20 0.72
HPGD P15428 5/20 0.72
SMN1; SMN2 Q16637 5/20 0.72
CYP3A4 P08684 5/20 0.72
IP6K2 Q9UHH9 5/20 0.72
MAPK1 P28482 3/20 0.72
ALDH1A1 P00352 3/20 0.72
FTO Q9C0B1 2/20 0.72
ST6GAL1 P15907 1/20 0.72
DHODH Q02127 1/20 0.72
ALOX12 P18054 3/20 0.71
TP53 P04637 3/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10037938 0.88 CSNK2A2 (0.74) POLHALOX5TNKSPARP1TNKS2
SCHEMBL3515838 0.87 HPGD (0.77) POLHALOX5TNKSPARP1TNKS2
SCHEMBL31552891 0.87 HPGD (0.77) POLHALOX5TNKSPARP1TNKS2
SCHEMBL29664594 0.86 ALOX5 (0.78) POLHALOX5TNKSPARP1TNKS2
SCHEMBL491032 0.86 ALOX5 (0.78) POLHALOX5TNKSPARP1TNKS2
SCHEMBL29678122 0.86 TNKS (1.00) POLHALOX5TNKSPARP1TNKS2
SCHEMBL30591365 0.86 ALOX5 (0.78) POLHALOX5TNKSPARP1TNKS2
SCHEMBL34405 0.86 TNKS (1.00) POLHALOX5TNKSPARP1TNKS2
SCHEMBL10068612 0.84 CSNK2A2 (0.69) POLHKDM4EMAPTHSD17B10HPGD
SCHEMBL345706 0.84 TNKS (1.00) POLHALOX5TNKSPARP1TNKS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110177237-A1 ANTIFOULING METHOD AND COMPOSITION USING CHROMEN-4-ONE DERIVATIVES THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) 2011-07-21 US claimed
WO-2005020881-A2 COMPOSITIONS OF FLAVONOIDS AND FLAVONOID-CONTAINING EXTRACTS AND THE TREATMENT OF DISEASES SHANGHAI COMMAN PHARMACEUTICAL CO. (US) 2005-03-10 WO claimed
US-20050049206-A1 Compositions of flavonoids and flavonoid-containing extracts and the treatment of diseases SHANGHAI COMMAN PHARMACEUTICAL CO. LTD. (CN) 2005-03-03 US claimed
US-8557331-B2 Antifouling method and composition using chromen-4-one derivatives THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) 2013-10-15 US disclosed
US-8557331-B2 Antifouling method and composition using chromen-4-one derivatives THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) 2013-10-15 US disclosed
US-8466195-B2 Methods and compositions for treating complications of diabetes and vascular diseases using flavones SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2013-06-18 US disclosed
US-8466195-B2 Methods and compositions for treating complications of diabetes and vascular diseases using flavones SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2013-06-18 US disclosed
US-20120016016-A1 METHODS AND COMPOSITIONS FOR TREATING COMPLICATIONS OF DIABETES AND VASCULAR DISEASES USING FLAVONES THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2012-01-19 US disclosed
US-20120016016-A1 METHODS AND COMPOSITIONS FOR TREATING COMPLICATIONS OF DIABETES AND VASCULAR DISEASES USING FLAVONES THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2012-01-19 US disclosed
US-20110177237-A1 ANTIFOULING METHOD AND COMPOSITION USING CHROMEN-4-ONE DERIVATIVES THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) 2011-07-21 US disclosed
WO-2010105253-A2 METHODS AND COMPOSITIONS FOR TREATING COMPLICATIONS OF DIABETES AND VASCULAR DISEASES USING FLAVONES THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2010-09-16 WO disclosed
WO-2009115051-A1 ANTIFOULING METHOD AND COMPOSITION USING CHROMEN-4-ONE DERIVATIVES THE HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY (CN) 2009-09-24 WO disclosed
US-20050049206-A1 Compositions of flavonoids and flavonoid-containing extracts and the treatment of diseases SHANGHAI COMMAN PHARMACEUTICAL CO. LTD. (CN) 2005-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120016016-A1 METHODS AND COMPOSITIONS FOR TREATING COMPLICATIONS OF DIABETES AND VASCULAR DISEASES USING FLAVONES SLC5A2, LIPG, TIE1 POLH 1988/4885ALOX5 66/4885TNKS 4131/4885
US-20050049206-A1 Compositions of flavonoids and flavonoid-containing extracts and the treatment of diseases FNTA, COLGALT1, F3 POLH 1080/4885ALOX5 407/4885TNKS 3854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.